Brought to you by 
Vical nets $31.7mm through FOPO
24 Jan 2011
Executive Summary
Vical Inc. (DNA delivery technologies) has netted $31.7mm through the follow-on public offering of 15mm common shares at $2.25 each. The financing comes at a time when partner Sanofi announced the failure of Phase III Temusi to produce blood vessel growth in critical limb ischemia patients and another ally, AnGes, pulled the Japanese regulatory filing for Collategene, also for critical limb ischemia.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vical nets $31.7mm through FOPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice